<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065762</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-174</org_study_id>
    <nct_id>NCT05065762</nct_id>
  </id_info>
  <brief_title>Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment</brief_title>
  <acronym>DCE</acronym>
  <official_title>Patient Preference for Treatment of Moderate-To-Severe Psoriasis in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to identify and weight the treatment attributes&#xD;
      from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 24, 2021</start_date>
  <completion_date type="Anticipated">February 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 17, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis (PsO) patient preferences of moderate-to-severe systemic treatment atrribute</measure>
    <time_frame>Within 60 minutes of survey/interview</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 1: Sex</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of PsO participants in Phase 1: Age</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of PsO participants in Phase 1: Time since PsO diagnosis</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of PsO participants in Phase 1: Severity of PsO</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of PsO participants in Phase 1: Current treatments for PsO</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of PsO participants in Phase 1: Time on current PsO treatment</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of PsO participants in Phase 1: Residence</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of PsO participants in Phase 1: Employment status</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of PsO participants in Phase 1: Education</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of PsO participants in Phase 1: Total number of previous treatments</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of PsO participants in Phase 1: Previous treatments for PsO</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of PsO participants in Phase 1: Level of income</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Sex</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Age</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Height</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Weight</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Residence</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Employment status</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Type of occupation</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Education</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time since PsO diagnosis</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Self-reported severity</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Current treatments for PsO</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time on current PsO treatment</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Previous treatments for PsO</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Comorbid conditions of interest</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Level of income</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <description>Participants with moderate-to-severe Psoriasis (PsO) in Japan who have been recruited based on eligibility criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2</arm_group_label>
    <description>Self-reported moderate-to-severe Psoriasis (PsO) participants in Japan</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 10 participants, diagnosed as moderate-to-severe Psoriasis (PsO) by a clinician&#xD;
        were included in the Phase 1 qualitative interview&#xD;
&#xD;
        A total of 200 participants, self-reported as moderate-to-severe PsO, were included in the&#xD;
        Phase 2 online survey&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of moderate-to-severe Psoriasis (PsO) by physician (phase 1) or&#xD;
             self-reported (phase 2)&#xD;
&#xD;
          -  Currently taking systemic psoriasis treatment&#xD;
&#xD;
          -  Japanese resident aged 20 years and older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable or unwilling to provide informed consent&#xD;
&#xD;
          -  Diagnosis of guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Morrisville</city>
        <state>North Carolina</state>
        <zip>27560</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>September 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Japan</keyword>
  <keyword>BMS-986165</keyword>
  <keyword>Observational study</keyword>
  <keyword>Moderate-to-severe PsO</keyword>
  <keyword>DCE (discrete choice experiment)</keyword>
  <keyword>Preferences</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

